Which has higher valuation & earnings, MESO or ENTX?

Entera Bio has lower revenue, but higher earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Entera Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mesoblast $120.25M 16.51 -$57.50M -$0.28 N/A Entera Bio $40K 12,211.56 -$11.44M -$0.35 N/A

Is MESO or ENTX more profitable?

Mesoblast's return on equity of 0.00% beat Entera Bio's return on equity. Company Net Margins Return on Equity Return on Assets Mesoblast N/A N/A N/A Entera Bio N/A -147.19% -103.22%

Does the media prefer MESO or ENTX?

In the previous week, Entera Bio had 2 more articles in the media than Mesoblast. MarketBeat recorded 7 mentions for Entera Bio and 5 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.83 beat Entera Bio's score of 0.25 indicating that Mesoblast is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesoblast 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Entera Bio 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, ENTX or VCEL?

Vericel has higher revenue and earnings than Entera Bio. Entera Bio is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Entera Bio $40K 12,211.56 -$11.44M -$0.35 N/A Vericel $276.26M 7.19 $16.52M $0.47 82.53

Is ENTX or VCEL more profitable?

Vericel has a net margin of 7.91% compared to Entera Bio's net margin of 0.00%. Vericel's return on equity of 6.91% beat Entera Bio's return on equity. Company Net Margins Return on Equity Return on Assets Entera Bio N/A -147.19% -103.22% Vericel 7.91% 6.91% 5.02%

Does the media favor ENTX or VCEL?

In the previous week, Entera Bio had 6 more articles in the media than Vericel. MarketBeat recorded 7 mentions for Entera Bio and 1 mentions for Vericel. Vericel's average media sentiment score of 1.73 beat Entera Bio's score of 0.25 indicating that Vericel is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entera Bio 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Vericel 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is LKFT or ENTX more profitable?

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Entera Bio's return on equity. Company Net Margins Return on Equity Return on Assets Lakefront Biotherapeutics American Depositary Shares N/A N/A N/A Entera Bio N/A -147.19% -103.22%

Does the media prefer LKFT or ENTX?

In the previous week, Lakefront Biotherapeutics American Depositary Shares and Lakefront Biotherapeutics American Depositary Shares both had 7 articles in the media. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 0.88 beat Entera Bio's score of 0.25 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lakefront Biotherapeutics American Depositary Shares 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Entera Bio 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, ZYME or ENTX?

Entera Bio has lower revenue, but higher earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Entera Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zymeworks $105.96M 18.42 -$81.13M -$2.02 N/A Entera Bio $40K 12,211.56 -$11.44M -$0.35 N/A

Is ZYME or ENTX more profitable?

Entera Bio has a net margin of 0.00% compared to Zymeworks' net margin of -405.31%. Zymeworks' return on equity of -72.30% beat Entera Bio's return on equity. Company Net Margins Return on Equity Return on Assets Zymeworks -405.31% -72.30% -37.18% Entera Bio N/A -147.19% -103.22%

Does the media prefer ZYME or ENTX?

In the previous week, Zymeworks had 1 more articles in the media than Entera Bio. MarketBeat recorded 8 mentions for Zymeworks and 7 mentions for Entera Bio. Zymeworks' average media sentiment score of 0.71 beat Entera Bio's score of 0.25 indicating that Zymeworks is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zymeworks 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Entera Bio 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ENTX or VIR?

In the previous week, Entera Bio had 6 more articles in the media than Vir Biotechnology. MarketBeat recorded 7 mentions for Entera Bio and 1 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 1.67 beat Entera Bio's score of 0.25 indicating that Vir Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entera Bio 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Vir Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Entera Bio (ENTX) Competitors

$2.81 -0.17 (-5.70%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$2.75 -0.06 (-2.10%)

As of 09/23/2026 07:56 PM Eastern

Compare

ENTX vs. MESO, VCEL, LKFT, ZYME, and VIR

Should you buy Entera Bio stock or one of its competitors? Entera Bio's main competitors and comparable companies include Mesoblast (MESO), Vericel (VCEL), Lakefront Biotherapeutics American Depositary Shares (LKFT), Zymeworks (ZYME), and Vir Biotechnology (VIR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Entera Bio compare to Mesoblast?

Mesoblast (NASDAQ:MESO) and Entera Bio (NASDAQ:ENTX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Mesoblast's return on equity of 0.00% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
Entera Bio	N/A	-147.19%	-103.22%

In the previous week, Entera Bio had 2 more articles in the media than Mesoblast. MarketBeat recorded 7 mentions for Entera Bio and 5 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.83 beat Entera Bio's score of 0.25 indicating that Mesoblast is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesoblast	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Entera Bio	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

1.4% of Mesoblast shares are held by institutional investors. Comparatively, 14.1% of Entera Bio shares are held by institutional investors. 18.8% of Mesoblast shares are held by company insiders. Comparatively, 10.6% of Entera Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Mesoblast has a beta of 2.12, indicating that its stock price is 112% more volatile than the broader market. Comparatively, Entera Bio has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market.

Mesoblast currently has a consensus price target of $39.00, indicating a potential upside of 155.07%. Entera Bio has a consensus price target of $9.00, indicating a potential upside of 220.28%. Given Entera Bio's stronger consensus rating and higher possible upside, analysts plainly believe Entera Bio is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Entera Bio has lower revenue, but higher earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Entera Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$120.25M	16.51	-$57.50M	-$0.28	N/A
Entera Bio	$40K	12,211.56	-$11.44M	-$0.35	N/A

Summary

Entera Bio beats Mesoblast on 8 of the 15 factors compared between the two stocks.

How does Entera Bio compare to Vericel?

Entera Bio (NASDAQ:ENTX) and Vericel (NASDAQ:VCEL) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Entera Bio has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market. Comparatively, Vericel has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market.

Vericel has a net margin of 7.91% compared to Entera Bio's net margin of 0.00%. Vericel's return on equity of 6.91% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entera Bio	N/A	-147.19%	-103.22%
Vericel	7.91%	6.91%	5.02%

In the previous week, Entera Bio had 6 more articles in the media than Vericel. MarketBeat recorded 7 mentions for Entera Bio and 1 mentions for Vericel. Vericel's average media sentiment score of 1.73 beat Entera Bio's score of 0.25 indicating that Vericel is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entera Bio	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vericel	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

14.1% of Entera Bio shares are owned by institutional investors. 10.6% of Entera Bio shares are owned by insiders. Comparatively, 7.6% of Vericel shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Vericel has higher revenue and earnings than Entera Bio. Entera Bio is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entera Bio	$40K	12,211.56	-$11.44M	-$0.35	N/A
Vericel	$276.26M	7.19	$16.52M	$0.47	82.53

Entera Bio currently has a consensus target price of $9.00, indicating a potential upside of 220.28%. Vericel has a consensus target price of $58.40, indicating a potential upside of 50.55%. Given Entera Bio's higher possible upside, analysts plainly believe Entera Bio is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Vericel	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Vericel beats Entera Bio on 10 of the 16 factors compared between the two stocks.

How does Entera Bio compare to Lakefront Biotherapeutics American Depositary Shares?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Entera Bio (NASDAQ:ENTX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

Lakefront Biotherapeutics American Depositary Shares presently has a consensus target price of $37.00, suggesting a potential upside of 20.44%. Entera Bio has a consensus target price of $9.00, suggesting a potential upside of 220.28%. Given Entera Bio's higher possible upside, analysts clearly believe Entera Bio is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	0 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.56
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Lakefront Biotherapeutics American Depositary Shares and Lakefront Biotherapeutics American Depositary Shares both had 7 articles in the media. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 0.88 beat Entera Bio's score of 0.25 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Entera Bio	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Entera Bio	N/A	-147.19%	-103.22%

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. Comparatively, 14.1% of Entera Bio shares are owned by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by insiders. Comparatively, 10.6% of Entera Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market. Comparatively, Entera Bio has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Entera Bio. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Entera Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$990.57M	2.04	$363.05M	-$1.41	N/A
Entera Bio	$40K	12,211.56	-$11.44M	-$0.35	N/A

Summary

Lakefront Biotherapeutics American Depositary Shares beats Entera Bio on 8 of the 14 factors compared between the two stocks.

How does Entera Bio compare to Zymeworks?

Zymeworks (NASDAQ:ZYME) and Entera Bio (NASDAQ:ENTX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership.

Entera Bio has lower revenue, but higher earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Entera Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$105.96M	18.42	-$81.13M	-$2.02	N/A
Entera Bio	$40K	12,211.56	-$11.44M	-$0.35	N/A

Zymeworks presently has a consensus price target of $41.00, suggesting a potential upside of 49.09%. Entera Bio has a consensus price target of $9.00, suggesting a potential upside of 220.28%. Given Entera Bio's higher probable upside, analysts plainly believe Entera Bio is more favorable than Zymeworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Zymeworks has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market. Comparatively, Entera Bio has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market.

In the previous week, Zymeworks had 1 more articles in the media than Entera Bio. MarketBeat recorded 8 mentions for Zymeworks and 7 mentions for Entera Bio. Zymeworks' average media sentiment score of 0.71 beat Entera Bio's score of 0.25 indicating that Zymeworks is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zymeworks	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Entera Bio	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Entera Bio has a net margin of 0.00% compared to Zymeworks' net margin of -405.31%. Zymeworks' return on equity of -72.30% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-405.31%	-72.30%	-37.18%
Entera Bio	N/A	-147.19%	-103.22%

92.9% of Zymeworks shares are held by institutional investors. Comparatively, 14.1% of Entera Bio shares are held by institutional investors. 33.5% of Zymeworks shares are held by insiders. Comparatively, 10.6% of Entera Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Zymeworks beats Entera Bio on 9 of the 16 factors compared between the two stocks.

How does Entera Bio compare to Vir Biotechnology?

Entera Bio (NASDAQ:ENTX) and Vir Biotechnology (NASDAQ:VIR) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

Entera Bio has higher earnings, but lower revenue than Vir Biotechnology. Entera Bio is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entera Bio	$40K	12,211.56	-$11.44M	-$0.35	N/A
Vir Biotechnology	$302.59M	6.20	-$437.99M	-$1.86	N/A

14.1% of Entera Bio shares are held by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are held by institutional investors. 10.6% of Entera Bio shares are held by insiders. Comparatively, 2.9% of Vir Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Entera Bio had 6 more articles in the media than Vir Biotechnology. MarketBeat recorded 7 mentions for Entera Bio and 1 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 1.67 beat Entera Bio's score of 0.25 indicating that Vir Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entera Bio	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vir Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Entera Bio currently has a consensus target price of $9.00, suggesting a potential upside of 220.28%. Vir Biotechnology has a consensus target price of $21.57, suggesting a potential upside of 94.51%. Given Entera Bio's higher probable upside, equities research analysts clearly believe Entera Bio is more favorable than Vir Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Entera Bio has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.63, indicating that its stock price is 63% more volatile than the broader market.

Entera Bio has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. Vir Biotechnology's return on equity of -29.99% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entera Bio	N/A	-147.19%	-103.22%
Vir Biotechnology	-638.88%	-29.99%	-23.62%

Summary

Vir Biotechnology beats Entera Bio on 10 of the 17 factors compared between the two stocks.

Get Entera Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENTX vs. The Competition

Export

Metric	Entera Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$518.03M	$3.98B	$7.32B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-8.03	13.88	274.06	25.69
Price / Sales	12,211.56	1,343.72	637.81	78.88
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	9.69	15.21	10.40	6.32
Net Income	-$11.44M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-7.26%	-1.72%	-0.69%	0.17%
1 Month Performance	-17.84%	-6.17%	-3.18%	-3.27%
1 Year Performance	56.11%	30.66%	15.13%	5.58%

Entera Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENTX Entera Bio	2.9389 of 5 stars	$2.81 -5.7%	$9.00 +220.3%	+53.6%	$518.03M	$40K	N/A	21	Analyst Forecast High Trading Volume
MESO Mesoblast	2.2633 of 5 stars	$15.92 +2.8%	$39.00 +145.0%	-6.3%	$2.07B	$120.25M	N/A	108	News Coverage
VCEL Vericel	3.8304 of 5 stars	$40.22 +1.7%	$58.40 +45.2%	+24.3%	$2.06B	$276.26M	85.58	398	Positive News
LKFT Lakefront Biotherapeutics American Depositary Shares	2.1832 of 5 stars	$30.19 +2.0%	$30.67 +1.6%	-8.4%	$1.99B	$1.26B	N/A	1,310	News Coverage Analyst Upgrade Gap Up High Trading Volume
ZYME Zymeworks	3.1182 of 5 stars	$27.57 +2.8%	$41.00 +48.7%	+68.1%	$1.96B	$105.96M	N/A	264

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENTX) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Entera Bio (ENTX) Competitors

ENTX vs. MESO, VCEL, LKFT, ZYME, and VIR

How does Entera Bio compare to Mesoblast?

Summary

How does Entera Bio compare to Vericel?

Summary

How does Entera Bio compare to Lakefront Biotherapeutics American Depositary Shares?

Summary

How does Entera Bio compare to Zymeworks?

Summary

How does Entera Bio compare to Vir Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTX vs. The Competition

Entera Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Entera Bio (ENTX) Competitors

ENTX vs. MESO, VCEL, LKFT, ZYME, and VIR

How does Entera Bio compare to Mesoblast?

Is MESO or ENTX more profitable?

Does the media prefer MESO or ENTX?

Do insiders and institutionals believe in MESO or ENTX?

Which has more risk and volatility, MESO or ENTX?

Do analysts recommend MESO or ENTX?

Which has higher valuation & earnings, MESO or ENTX?

Summary

How does Entera Bio compare to Vericel?

Which has more risk & volatility, ENTX or VCEL?

Is ENTX or VCEL more profitable?

Does the media favor ENTX or VCEL?

Do insiders & institutionals believe in ENTX or VCEL?

Which has better valuation & earnings, ENTX or VCEL?

Do analysts recommend ENTX or VCEL?

Summary

How does Entera Bio compare to Lakefront Biotherapeutics American Depositary Shares?

Do analysts rate LKFT or ENTX?

Does the media prefer LKFT or ENTX?

Is LKFT or ENTX more profitable?

Do insiders and institutionals hold more shares of LKFT or ENTX?

Which has more risk & volatility, LKFT or ENTX?

Which has stronger valuation and earnings, LKFT or ENTX?

Summary

How does Entera Bio compare to Zymeworks?

Which has higher valuation and earnings, ZYME or ENTX?

Do analysts recommend ZYME or ENTX?

Which has more volatility and risk, ZYME or ENTX?

Does the media prefer ZYME or ENTX?

Is ZYME or ENTX more profitable?

Do institutionals & insiders hold more shares of ZYME or ENTX?

Summary

How does Entera Bio compare to Vir Biotechnology?

Which has stronger valuation & earnings, ENTX or VIR?

Do institutionals and insiders have more ownership in ENTX or VIR?

Does the media refer more to ENTX or VIR?

Do analysts rate ENTX or VIR?

Which has more volatility and risk, ENTX or VIR?

Is ENTX or VIR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTX vs. The Competition

Entera Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools